Corebridge Financial’s Revance Therapeutics, Inc. RVNC Stock Holding History

Corebridge Financial’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-51,761	Closed	-$157K	–	3035
2024 Q4	$157K	Sell	51,761 -3,907	-7%	-$17K	﹤0.01%	2312
2024 Q3	$289K	Sell	55,668 -343	-0.6%	-$1.71K	﹤0.01%	2015
2024 Q2	$144K	Buy	+56,011	New	+$191K	﹤0.01%	2389

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Corebridge Financial's RVNC Position: Q1 2025 in Review

Corebridge Financial sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 51,761 shares — an estimated $157K sold.

Corebridge Financial first reported a position in RVNC in Q2 2024 and held it in 3 quarters. The position peaked at $289K in Q3 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Corebridge Financial reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Corebridge Financial sold 51,761 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $157K.
Corebridge Financial first reported a position in Revance Therapeutics, Inc. in Q2 2024 and held it in 3 quarters.
Corebridge Financial's Revance Therapeutics, Inc. position peaked at $289K in Q3 2024.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Corebridge Financial's 13F filing for Q1 2025, filed 14 May 2025.